Demystifying brain penetration in central nervous system drug discovery

Journal of Medicinal Chemistry

Volumn 56, Issue 1, 2013, Pages 2-12

  Di, Li ^a   Rong, Haojing ^a   Feng, Bo ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; HUMAN; NONHUMAN; PERMEABILITY; PLASMA; PROTEIN BINDING; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PERMEABILITY; PROTEIN BINDING;

EID: 84872319925     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301297f     Document Type: Review

References (71)

1. Kola, I.; Landis, J. Opinion: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3, 711-716
2. Pardridge, W. M. Crossing the blood-brain barrier: are we getting it right? Drug Discovery Today 2001, 6, 1-2
3. Stovall, S. GSK makes savings by exiting risky R&D, but at what cost? World Street J. 2012, July 28.
4. Abbott, N. J.; Patabendige, A. A. K.; Dolman, D. E. M.; Yusof, S. R.; Begley, D. J. Structure and function of the blood-brain barrier Neurobiol. Dis. 2010, 37, 13-25
5. Di, L.; Kerns, E. H.; Carter, G. T. Strategies to assess blood-brain barrier penetration Expert Opin. Drug Discovery 2008, 3, 677-687
6. Giacomini, K. M.; Huang, S.-M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L. R.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Wah Yee, S.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9, 215-236
7. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
8. Liu, X.; Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Worboys, P. D.; Monshouwer, M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid Drug Metab. Dispos. 2009, 37, 787-793
9. Lu, Y.; Zhang, L.; Nolan, C. E.; Becker, S. L.; Atchison, K.; Robshaw, A. E.; Pustilnik, L. R.; Osgood, S. M.; Miller, E. H.; Stepan, A. F.; Subramanyam, C.; Efremov, I.; Hallgren, A. J.; Riddell, D. Quantitative pharmacokinetic/ pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors J. Pharmacol. Exp. Ther. 2011, 339, 922-934
10. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E. C. A.; Kasman, I. N.; LaPerle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab. Dispos. 2005, 33, 165-174
11. Maurer, T. S.; DeBartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice Drug Metab. Dispos. 2005, 33, 175-181
12. Friden, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids J. Med. Chem. 2009, 52, 6233-6243
13. Sadiq, M. W.; Borgs, A.; Okura, T.; Shimomura, K.; Kato, S.; Deguchi, Y.; Jansson, B.; Bjoerkman, S.; Terasaki, T.; Hammarlund-udenaes, M. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo J. Pharm. Sci. 2011, 100, 3912-3923
14. Su, T. Z.; Feng, M. R.; Weber, M. L. Mediation of highly concentrative uptake of pregabalin by l -type amino acid transport in Chinese hamster ovary and Caco-2 cells J. Pharmacol. Exp. Ther. 2005, 313, 1406-1415
15. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A. On the rate and extent of drug delivery to the brain Pharm. Res. 2008, 25 (8) 1737-1750
16. Benet, L. Z.; Hoener, B.-A. Changes in plasma protein binding have little clinical relevance Clin. Pharmacol. Ther. 2002, 71, 115-121
17. Price, D. A.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review Expert Opin. Drug Metab. Toxicol. 2009, 5, 921-931
18. Rong, H.; Feng, B.; Di, L. Integrated Approaches to Blood Brain Barrier. In Encyclopedia of Drug Metabolism and Interactions; Lyubimov, A. V., Ed.; John Wiley & Sons: Hoboken, NJ, 2012.
19. Lin, J., H. CSF as a surrogate for assessing CNS exposure: an industrial perspective Curr. Drug Metab. 2008, 9, 46-59
20. Venkatakrishnan, K.; Tseng, E.; Nelson, F. R.; Rollema, H.; French, J. L.; Kaplan, I. V.; Horner, W. E.; Gibbs, M. A. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures Drug Metab. Dispos. 2007, 35, 1341-1349
21. Hammarlund-Udenaes, M.; Bredberg, U.; Friden, M. Methodologies to assess brain drug delivery in lead optimization Curr. Top. Med. Chem. 2009, 9, 148-162
22. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB J. Pharm. Sci. 2009, 98, 4429-4468
23. Liu, X.; Chen, C. Strategies to optimize brain penetration in drug discovery Curr. Opin. Drug Discovery Dev. 2005, 8, 505-512
24. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 2008, 36, 268-275
25. Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J. Pharmacol. Exp. Ther. 2010, 333, 788-796
26. Syvaenen, S.; Lindhe, O.; Palner, M.; Kornum, B. R.; Rahman, O.; Laangstroem, B.; Knudsen, G. M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab. Dispos. 2009, 37, 635-643
27. Hochman, J.; Mei, Q.; Yamazaki, M.; Tang, C.; Prueksaritanont, T.; Bock, M.; Ha, S.; Lin, J. Role of mechanistic transport studies in lead optimization Biotechnol.: Pharm. Aspects 2006, 4, 25-47
28. Rautio, J., Ed. Prodrugs and Targeted Delivery: Towards Better ADME Properties; Wiley-VCH: Weinheim, Germany, 2011; Vol. 54, p 253.
29. Roth, M.; Obaidat, A.; Hagenbuch, B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies Br. J. Pharmacol. 2012, 165, 1260-1287
30. Cheng, Z.; Liu, H.; Yu, N.; Wang, F.; An, G.; Xu, Y.; Liu, Q.; Guan, C.-b.; Ayrton, A. Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier Xenobiotica 2012, 42, 880-890
31. Bhardwaj, R. K.; Herrera-Ruiz, D.; Sinko, P. J.; Gudmundsson, O. S.; Knipp, G. Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells J. Pharmacol. Exp. Ther. 2005, 314, 1093-1100
32. Kusuhara, H.; Sugiyama, Y. Active efflux across the blood-brain barrier: role of the solute carrier family NeuroRx 2005, 2, 73-85
33. Smith, Q. R.; David, A. D. In situ brain perfusion technique Methods Mol. Med. 2003, 89, 209-218
34. Takasato, Y.; Rapoport, S. I.; Smith, Q. R. An in situ brain perfusion technique to study cerebrovascular transport in the rat Am. J. Physiol. 1984, 247, H484-H493
35. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
36. Tsinman, O.; Tsinman, K.; Sun, N.; Avdeef, A. Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model Pharm. Res. 2011, 28, 337-363
37. Garberg, P.; Ball, M.; Borg, N.; Cecchelli, R.; Fenart, L.; Hurst, R. D.; Lindmark, T.; Mabondzo, A.; Nilsson, J. E.; Raub, T. J.; Stanimirovic, D.; Terasaki, T.; Oeberg, J. O.; Oesterberg, T. In vitro models for the blood-brain barrier Toxicology in Vitro 2005, 19, 299-334
38. Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Development of a computational approach to predict blood-brain barrier permeability Drug Metab. Dispos. 2004, 32, 132-139
39. Bickel, U. How to measure drug transport across the blood-brain barrier NeuroRx 2005, 2, 15-26
40. Di, L.; Umland, J. P.; Trapa, P. E.; Maurer, T. S. Impact of recovery on fraction unbound using equilibrium dialysis J. Pharm. Sci. 2012, 101, 1327-1335
41. http://htdialysis.com/.
42. http://www.piercenet.com/browse.cfm?fldID=8C6CA217-75C3-4019-AE9C- D48FF4C00EC6.
43. http://www.admecell.com/transil-pp/.
44. Plum, A.; Larsen, P. S.; Larsen, U. D.; Kristensen, J. B.; Jansen, J. A. Determination of in vitro plasma protein binding of insulin aspart and insulin detemir by equilibrium dialysis Diabetologia 1999, A236
45. Di, L.; Umland, J. P.; Chang, G. C.; Huang, Y.; Lin, Z. J.; Scott, D. O.; Troutman, M. D.; Liston, T. E. Species independence in brain tissue binding using brain homogenates Drug Metab. Dispos. 2011, 39, 1270-1277
46. Hong, L.; Jiang, W.; Pan, H.; Jiang, Y.; Zeng, S.; Zheng, W. Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese Drug Metab. Dispos. 2011, 39, 1904-1909
47. Liu, X.; Vilenski, O.; Kwan, J.; Apparsundaram, S.; Weikert, R. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats Drug Metab. Dispos. 2009, 37, 1548-1556
48. Watson, J.; Wright, S.; Lucas, A.; Clarke, K. L.; Viggers, J.; Cheetham, S.; Jeffrey, P.; Porter, R.; Read, K. D. Receptor occupancy and brain free fraction Drug Metab. Dispos. 2009, 37, 753-760
49. Cole, S.; Bagal, S.; El-Kattan, A.; Fenner, K.; Hay, T.; Kempshall, S.; Lunn, G.; Varma, M.; Stupple, P.; Speed, W. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration Xenobiotica 2012, 42, 11-27
50. University of Washington Drug Interaction Database. http://www. druginteractioninfo.org/.
51. Wang, E.-J.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein Drug Metab. Dispos. 2001, 29, 1080-1083
52. Obradovic, T.; Dobson, G. G.; Shingaki, T.; Kungu, T.; Hidalgo, I. J. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein Pharm. Res. 2007, 24, 318-327
53. Ramanathan, R.; Reyderman, L.; Kulmatycki, K.; Su, A. D.; Alvarez, N.; Chowdhury, S. K.; Alton, K. B.; Wirth, M. A.; Clement, R. P.; Statkevich, P.; Patrick, J. E. Disposition of loratadine in healthy volunteers Xenobiotica 2007, 37, 753-769
54. Zhou, L.; Schmidt, K.; Nelson, F. R.; Zelesky, V.; Troutman, M. D.; Feng, B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice Drug Metab. Dispos. 2009, 37, 946-955
55. Polli, J. W.; Olson, K. L.; Chism, J. P.; John-Williams, L. S.; Yeager, R. L.; Woodard, S. M.; Otto, V.; Castellino, S.; Demby, V. E. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N -{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab. Dispos. 2009, 37, 439-442
56. Campbell, M. A.; Perrier, D. G.; Dorr, R. T.; Alberts, D. S.; Finley, P. R. Methotrexate: bioavailability and pharmacokinetics Cancer Treat. Rep. 1985, 69, 833-838
57. Bartels, A.; Willemsen, A.; Kortekaas, R.; de Jong, B.; de Vries, R.; de Klerk, O.; van Oostrom, J.; Portman, A.; Leenders, K. Decreased blood brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA J. Neural Transm. 2008, 115, 1001-1009
58. Vogelgesang, S.; Glatzel, M.; Walker, L. C.; Kroemer, H. K.; Aguzzi, A.; Warzok, R. W. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease Acta Neuropathol. 2006, 111, 436-443
59. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans Pharmacogenetics 2002, 12, 535-541
60. 11C]verapamil as a probe for P-glycoprotein function Psychiatry Res., Neuroimaging 2010, 183, 151-156
61. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55, 4877-4895
62. Sasongko, L.; Link, J. M.; Muzi, M.; Mankoff, D. A.; Yang, X.; Collier, A. C.; Shoner, S. C.; Unadkat, J. D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography Clin. Pharmacol. Ther. 2005, 77, 503-514
63. Hendrikse, N. H.; Schinkel, A. H.; De Vries, E. G. E.; Fluks, E.; Van Der Graaf, W. T. A.; Willemsen, A. T. M.; Vaalburg, W.; Franssen, E. J. F. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography Br. J. Pharmacol. 1998, 124, 1413-1418
64. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios Drug Metab. Dispos. 2007, 35, 660-666
65. Lin, J. H. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today 2004, 40, 5-22
66. Breedveld, P.; Beijnen, J. H.; Schellens, J. H. M. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs Trends Pharmacol. Sci. 2006, 27, 17-24
67. Eyal, S.; Hsiao, P.; Unadkat, J. D. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol. Ther. 2009, 123, 80-104
68. 11C-labeled topotecan using small-animal positron emission tomography Nucl. Med. Biol. 2011, 38, 707-714
69. 11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data Clin. Pharmacol. Ther. (N. Y., NY, U. S.) 2012, 91, 227-233
70. Shen, D. D.; Artru, A. A.; Adkison, K. K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics Adv. Drug Delivery Rev. 2004, 56, 1825-1857
71. Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; El-kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a new permeability assay using low-efflux MDCKII cells J. Pharm. Sci. 2011, 100, 4974-4985